Lord Freyberg – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Lord Freyberg on 2016-09-05.
To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 25 July (HL1340), what assessment they have made of the relative clinical benefits of the drug lenvatinib as opposed to sorafenib.
Lord Prior of Brampton
Ministers asked the National Institute for Health and Care Excellence (NICE) to develop technology appraisal guidance on the use of lenvatinb for the treatment of thyroid cancer on 22 July 2016. NICE plans to develop guidance on lenvatinib and sorafenib through the same technology appraisal and currently expects to publish draft guidance in October 2017.
In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence and on the patient’s individual clinical circumstances.
